Please assess the completion status of the following clinical trial:

Trial Title: AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed diagnosis of 1 of the following:~  * Non-small cell lung cancer (NSCLC) (closed to accrual as of 8/9/07) meeting 1 of the following stage criteria:~    * Stage IIIB disease~      * Patients without pleural effusion who are not candidates for combined modality treatment OR who were treated at centers where combined modality treatment is not considered standard treatment are eligible~   * Stage IV disease~   * Local or metastatic failure after prior surgery and/or radiotherapy~ * Colorectal cancer~    * Metastatic disease~   * Considered suitable for first-line therapy with capecitabine~ * Other tumor types~    * Suitable for treatment with capecitabine~   * No more than 2 prior chemotherapy regimens for advanced or metastatic disease~* Incurable by radiotherapy or surgery~* Clinically or radiologically documented disease~  * No tumor marker elevation as the only evidence of disease~* No necrotic or hemorrhagic tumor or metastases~* No untreated brain or meningeal metastases~  * Patients with previously treated stable brain metastases (by radiography or clinical exam) are eligible provided they are asymptomatic and do not require corticosteroids~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* At least 12 weeks (colorectal cancer patients)~Hematopoietic~* Hemoglobin adequate~  * Anemia allowed provided patient is well compensated with no evidence of recent bleeding~* Absolute granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* No overt bleeding (i.e., ≥ 30 mL/episode) within the past 3 months~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT or AST ≤ 2 times ULN (5 times ULN for documented liver metastases)~Renal~* Creatinine ≤ 1.5 times ULN OR~* Creatinine clearance ≥ 50 mL/min~* No proteinuria \> grade 1~Cardiovascular~* Resting systolic blood pressure ≤ 150 mm Hg AND/OR resting diastolic blood pressure ≤ 100 mm Hg (in the presence or absence of a stable dose of antihypertensive medication)~* Mean QTc ≤ 470 msec (with Bazetts correction) by ECG~* LVEF \> 50% for patients with prior anthracyclines/trastuzumab or cardio-toxic agents~* No untreated or uncontrolled cardiovascular condition~* No symptomatic cardiac dysfunction~* No poorly controlled hypertension~* No history of labile hypertension~* No history of poor compliance with antihypertensive medication~* No history of familial long QT syndrome~Pulmonary~* No clinically relevant hemoptysis (i.e., ≥ 5 mL fresh blood) within the past 4 weeks~  * Patients with only flecks of blood in their sputum are eligible~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective (double-method for females; barrier method for males) contraception~* No prior allergic reaction to drugs containing Cremophor EL® (NSCLC patients \[closed to accrual as of 8/9/07\])~* No peripheral neuropathy \> grade 1 (NSCLC patients \[closed to accrual as of 8/9/07\])~* No dihydropyrimidine dehydrogenase deficiency (colorectal cancer patients)~* No history of severe hand-foot syndrome after treatment with fluoropyrimidines (colorectal cancer patients)~* No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or other curatively treated solid tumor~* No active or uncontrolled infection~* No other serious illness or medical condition that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior antiangiogenesis therapy~Chemotherapy~* At least 4 weeks since prior single-agent non-platinum-containing chemotherapy (6 weeks for nitrosoureas or mitomycin) for metastatic disease (NSCLC patients \[closed to accrual as of 8/9/07\])~  * No more than 1 prior single-agent non-platinum-containing chemotherapy regimen for metastatic disease~* At least 6 months since prior adjuvant or neoadjuvant chemotherapy~* No prior taxane therapy (NSCLC patients \[closed to accrual as of 8/9/07\])~* No prior chemotherapy for metastatic disease (colorectal cancer patients)~* No prior capecitabine (colorectal cancer patients)~Endocrine therapy~* See Disease Characteristics~* At least 4 weeks since prior corticosteroids~Radiotherapy~* See Disease Characteristics~* At least 21 days since prior palliative radiotherapy except for low-dose non-myelosuppressive radiotherapy with approval~* At least 6 months since prior adjuvant radiotherapy~Surgery~* See Disease Characteristics~* At least 14 days since prior major surgery~Other~* Recovered from prior therapy~* At least 14 days since prior epidermal growth factor receptor inhibitor therapy~* Concurrent oral anticoagulants (e.g., warfarin) allowed provided INR is strictly monitored~* No other concurrent investigational therapy~* No other concurrent anticancer therapy~* No concurrent prophylactic pyridoxine (vitamin B_6) for hand-foot syndrome (colorectal or other tumor type patients)~  * Use of pyridoxine after the onset of hand-foot syndrome allowed at the discretion of the physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- AZD2171 + Standard chemotherpay regimens (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete